DNA Link, Inc. announced that it expects to receive KRW 7 billion in funding from Synergy IB Investment Co., Ltd.
January 09, 2018
Share
DNA Link, Inc. (KOSDAQ:A127120) announced a private placement of series 6 unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 7,000,000,000 on January 10, 2018. The transaction will involve participation from Synergy Bio Fund 2, a fund managed by Synergy IB Investment Co., Ltd. The bonds will not carry any coupon rate and will mature on January 12, 2021. The bonds will be convertible into 1,205,026 shares of the company at a fixed conversion price of KRW 5,809 from January 12, 2019 to December 12, 2020. The expected payment date of the transaction is January 12, 2018. The transaction was approved by the board of directors of the company.
DNA LINK, INC. is a Korea-based company engaged in the genetics research business. The Company provides genome biomarkers excavation products through integrated genomic analysis and integrated clinical information analysis including high-quality data products according to genomic analysis, interpretation of analysis results, and technologies of molecular diagnostic kit production under the brand name of enhanced genome integration system (EGIS). The Company also provides personal genome analysis service products under the brand name of deoxyribonucleic acid personalized services (DNAGPS).
DNA LINK, INC. 
